Abstract Despite the clinical success of immune checkpoint blockade (ICB) in several malignancies, a majority of patients failed to achieve clinical response. A deeper understanding of the cellular and molecular mechanisms underlying ICB resistance is essential for advancing precision immunotherapy. In the present study, we analyzed the complex transcriptional profiles of 663,526 single cell data across eight different cancer types with clinical response to ICB therapy. Through integrative analysis, we delineated the transcriptional heterogeneity of exhausted CD8+ T cells and immunosuppressive macrophages and assessed their contribution to ICB treatment outcomes. Exhausted T cells demonstrated a wide spectrum of exhaustion states that stratified patients by clinical response. Notably, terminally exhausted T cells were particularly enriched in non-responders and exhibited high expressions of TIGIT, HAVCR2, and CTNNB1-driven WNT signaling activity, while responders were marked by activation of cytotoxic effectors and NF-κB transcriptional regulators. Immunosuppressive macrophages were functionally associated with terminal T cell exhaustion via aberrant activation of CD137 signaling axis. Transcriptional regulatory network analysis further revealed key transcriptional factors and immune checkpoint molecules that are differentially expressed across all cell states, offering new therapeutic targets. Our study provides a comprehensive single-cell atlas of immune cell states predictive of ICB response, uncovering substantial cellular and transcriptional heterogeneity and crosstalk between exhausted T cells and macrophage populations. These findings present mechanistic insights into cellular programs that can be therapeutically modulated to overcome ICB resistance. Citation Format: Dayoung Lee, Ji Yoon Lee, Jiwon Kim, You Jin Song, Namsung Moon, Juyoung Lee, Harim Koo, Jason K. Sa. Comprehensive single-cell atlas of immune ecosystem in response to immune checkpoint blockade therapy abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2814.
Lee et al. (Fri,) studied this question.